Security key
74065P101
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD)
CUSIP: 74065P101
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 27,161,835
- Total 13F value
- $39,111,943
- Share change
- -26,120
- SEC-reported price per share
- $1.44
- Number of holders
- 45
- Value change
- +$249,044
- Number of buys
- 12
- Number of sells
- 30
- Shares outstanding
- 64,968,808
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
45
Top holders
10
PRLD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Prelude Therapeutics Inc SEC filings
Prelude Therapeutics Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74065P101
Recent filing periods:
Ownership snapshot
Top reported holders of PRLD - Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Jun 2025
13F
Lead comparable stake: 17%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 17%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
17%
BAKER BROS. ADVISORS LP
16%
VANGUARD GROUP INC
1.4%
PRICE T ROWE ASSOCIATES INC /MD/
1.4%
RENAISSANCE TECHNOLOGIES LLC
0.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
17%
|
$8,829,952
10,909,256 shares
|
— | 30 Jun 2025 |
| BAKER BROS. ADVISORS LP |
13F
Company
|
16%
|
$8,194,223
10,123,824 shares
|
— | 30 Jun 2025 |
| VANGUARD GROUP INC |
13F
Company
|
1.4%
|
$754,450
932,570 shares
|
— | 30 Jun 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
1.4%
|
$743,000
927,608 shares
|
— | 30 Jun 2025 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
0.9%
|
$470,909
581,800 shares
|
— | 30 Jun 2025 |
| ACADIAN ASSET MANAGEMENT LLC |
13F
Company
|
0.83%
|
$436,000
540,565 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
45
Shares
27,161,835
Rows available
45
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
49
Q3 2025 holders
45
Holder diff
-4
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend